

Chemicals/Finland, November 4, 2022 Company update

## Growth and EBIT potential remain

Exel's Q3 results didn't meet our estimates, but long-term EBIT potential remains significant even if it materializes somewhat slower than we previously estimated.

### Top and bottom line a bit shy but no major issues

Exel's Q3 revenue was EUR 33.8m vs our EUR 37.5m estimate. The two largest regions, Europe and North America, continued to grow at a rate of some 5% y/y while Asia-Pacific declined by 6%. The largest customer segments landed close to our estimates, while relative softness within the smaller segments added up and hence Exel's volumes were not quite as high as we expected. The relative lack in volumes also left the EUR 1.8m adj. EBIT muted vs our EUR 2.7m estimate. The summer months were quiet in terms of new orders however the levels have begun to improve over the autumn. Exel left its guidance unchanged; in our view Q4 EBIT is set to improve y/y as the comparison figure is low, while there should be potential for at least some improvement g/q.

### Long-term CAGR should remain around 5-10%

Exel's long-term drivers are in place as before and we believe the company has been able to find the right types of customer accounts. The 6.7% adj. EBIT margin seen this year is not too bad, yet there should be plenty of upside left beyond that level. The consolidation of the two Chinese plants yields annual cost savings of EUR 0.7m, while wind power is likely to remain an important driver next year. The Indian JV may prove useful in this respect. The 24% growth seen last year was a rate very difficult to sustain for long, and Exel's top line may not grow much this year, but in our view Exel's accounts should still support long-term CAGR of some 5-10%. Such rates, combined with further margin upside, mean there's still meaningful EBIT potential left.

### Valuation not demanding even if growth slows a bit

Exel is valued at slightly above 8x EV/EBIT on our FY '23 estimates, which is not a particularly high level considering our respective 7.5% EBIT margin estimate is well below the long-term benchmark level of 10% the company has been able to touch on a few occasions with significantly lower top line. In our view Exel's key customer accounts could help the company grow even in a more challenging macro environment, however short order visibility is one factor limiting earnings multiples potential. We update our TP to EUR 6.5 (8.5) and retain our BUY rating.



■ BUY ☐ HOLD ■ SELL

www.exelcomposites.com

joonas.ilvonen@evli.com

Joonas Ilvonen

+358 44 430 9071

KEY FIGU	RES									
	Sales EURm	EBIT EURm	EBIT %	FCF EURm	EPS EUR	P/E (x)	EV/Sales (x)	EV/EBIT (x)	FCF yield %	DPS EUR
2020	108.6	9.4	8.7%	0.5	0.45	16.4	1.1	12.5	0.6	0.20
2021	134.4	3.7	2.8%	-6.2	0.14	57.0	1.0	34.9	-6.5	0.20
2022E	142.3	7.1	5.0%	6.4	0.65	8.0	0.7	13.2	10.4	0.25
2023E	150.8	11.3	7.5%	5.9	0.63	8.3	0.6	8.1	9.5	0.30
2024E	158.4	14.3	9.0%	9.2	0.90	5.8	0.5	6.0	14.9	0.32
Market cap	, EURm		62 G	earing 2022E,	0/0		87.9 CAGR	EPS 2021-2	4, %	86.5
Net debt 20	022E, EURm		32 Pi	rice/book 2022	2E		1.7 CAGR	sales 2021-	24, %	5.6
Enterprise	value, EURm		94 D	ividend yield 2	2022E, %		4.8 ROE 2	022E, %		22.9
Total assets	s 2022E, EURn	n	122 Ta	ıx rate 2022E,	0/0		29.0 ROCE	2022E, %		8.7
Goodwill 2	022E, EURm		13 Ec	quity ratio 202	22E, %		30.0 PEG, P	P/E 22/CAGR		0.4

Web site

Analyst

E-mail

Telephone



-11%

-44 %

-1%

Chemicals/Finland, November 4, 2022 Company update

## Estimates and peer group multiples

Exel Composites	2019	2020	Q1'21	Q2'21	Q3'21	Q4'21	2021	Q1'22	Q2'22	Q3'22	Q4'22e	2022e
Buildings and infrastructure	23.5	23.5	7.0	9.5	8.1	8.4	32.9	7.7	8.9	7.8	7.8	32.2
Equipment and other industries	18.6	19.5	5.6	5.2	5.4	7.1	23.4	7.4	5.9	5.6	7.3	26.0
Wind power	23.6	28.1	7.4	7.8	8.6	8.3	32.1	6.8	6.5	8.0	7.2	28.5
Machinery and electrical	14.4	15.5	3.6	4.3	4.8	4.9	17.6	4.3	5.3	5.0	5.1	19.6
Transportation	13.1	10.2	2.5	2.7	2.1	2.9	10.2	3.1	7.2	3.7	3.9	17.9
Defense	2.3	5.3	2.2	1.8	2.2	2.5	8.7	2.1	1.6	2.0	2.6	8.2
Telecommunications	8.2	6.5	2.5	2.3	2.3	2.3	9.5	2.8	2.8	1.7	2.4	9.8
Revenue	103.8	108.6	31.0	33.5	33.4	36.5	134.4	34.2	38.1	33.8	36.3	142.3
y/y change, %	7 %	5 %	11 %	23 %	28 %	33 %	24 %	10 %	14 %	1 %	-1 %	6 %
Adjusted EBIT	7.2	9.7	2.5	2.5	0.1	1.0	6.0	2.2	3.1	1.8	2.4	9.5
EBIT	5.1	9.4	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	1.7		7.1
-margin, %	6.9 %	8.9 %	7.9 %	7.3 %	0.3 %	2.8 %	4.5 %	6.4 %	8.2 %	5.4 %	6.6 %	6.7 %
-margin (reported), %	4.9 %	8.7 %	7.8 %	7.0 %	-5.1 %	1.8 %	2.8 %	0.1 %	7.9 %	5.0 %		5.0 %

Source: Evli Research

	MCAP		EV/EBITDA			EV/EBIT			EBIT-%	
EXEL COMPOSITES PEER GROUP	MEUR	22	23	24	22	23	24	22	23	24
Hexagon Composites	430		95.8x	21.7x				-9.3 %	-5.9 %	-2.5 %
Hexcel	4748	17.6x	14.2x	12.2x	30.3x	22.8x	17.9x	11.4 %	13.3 %	15.4 %
Avient	2635	9.4x	9.3x	8.3x	14.0x	14.2x	12.1x	8.9 %	10.4 %	11.5 %
SGL Carbon	886	6.2x	6.8x	6.1x	10.0x	11.1x	9.8x	9.4 %	8.4 %	9.1 %
TPI Composites	386	15.9x	8.5x	5.2x		23.7x	8.3x	-1.0 %	1.6 %	4.1 %
Peer Group Average	1817	12.3x	26.9x	10.7x	18.1x	18.0x	12.0x	3.9 %	5.6 %	7.5 %
Peer Group Median	886	12.6x	9.3x	8.3x	14.0x	18.5x	10.9x	8.9 %	8.4 %	9.1 %
Exel Composites (Evli est.)	62	6.7x	5.0x	4.0x	13.2x	8.1x	6.0x	5.0 %	7.5 %	9.0 %

-51 %

-5 %

-56 %

-45 %

-46 %

-47 %

Exel Composites prem./disc. to peer median

Chemicals/Finland, November 4, 2022 Company update

VALUATION RESULTS	BASE CASE DETAILS	VALUATION ASSUMPTIONS	ASSUMPTIONS FOR WACC	
Current share price	5.20 PV of Free Cash Flow	75 Long-term growth, %	1.5 Risk-free interest rate, %	2.25
DCF share value	11.42 PV of Horizon value	99 WACC, %	8.5 Market risk premium, %	5.8
Share price potential, %	119.6 Unconsolidated equity	O Spread, %	0.5 Debt risk premium, %	3.3
Maximum value	12.6 Marketable securities	16 Minimum WACC, %	8.0 Equity beta coefficient	1.00
Minimum value	10.4 Debt - dividend	-54 Maximum WACC, %	9.0 Target debt ratio, %	10
Horizon value, %	56.9 Value of stock	136 Nr of shares, Mn	11.9 Effective tax rate, %	21

DCF valuation, EURm	2021	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	Horizon
Net sales	134	142	151	158	163	167	171	174	177	181	184	186
Sales growth, %	23.7	5.9	6.0	5.0	3.0	2.5	2.0	2.0	2.0	2.0	1.5	1.5
Operating income (EBIT)	4	7	11	14	16	18	18	19	20	21	21	21
Operating income margin, %	2.8	5.0	7.5	9.0	10.0	10.5	10.5	11.0	11.5	11.5	11.5	11.5
+ Depreciation+amort.	8	7	7	7	7	7	7	7	7	7	7	
EBITDA	12	14	18	21	23	25	25	26	27	28	28	
- Paid taxes	-3	-2	-3	-4	<b>-</b> 5	<b>-</b> 5	<b>-</b> 5	-6	-6	-6	-6	
- Change in NWC	-5	-1	-1	-1	-1	-1	0	0	0	0	0	
NWC / Sales, %	12.7	12.7	12.8	12.8	12.8	12.9	12.9	12.9	12.9	12.9	12.9	
+ Change in other liabs	0	0	0	0	0	0	0	0	0	0	0	
- Operative CAPEX	-10	-6	-6	-6	-6	-7	-7	-7	-7	-7	-7	
opCAPEX / Sales, %	8.2	5.1	4.9	4.7	4.6	4.6	4.2	4.2	4.2	4.2	4.1	
- Acquisitions	0	0	0	0	0	0	0	0	0	0	0	
+ Divestments	0	0	0	0	0	0	0	0	0	0	0	
- Other items	0	0	0	0	0	0	0	0	0	0	0	
= FCFF	-5	5	7	10	12	12	12	13	14	14	15	210
= Discounted FCFF		5	7	8	9	9	8	8	8	7	7	99
= DFCF min WACC		5	7	8	9	9	8	8	8	8	7	112
= DFCF max WACC		5	7	8	9	9	8	8	7	7	7	89

Chemicals/Finland, November 4, 2022 Company update

### INTERIM FIGURES

EVLI ESTIMATES, EURm	2021Q1	202102	2021Q3	2021Q4	2021	2022Q1	2022Q2	2022Q3	2022Q4E	2022E	2023E	2024E
Net sales	31.0	33.5	33.4	36.5	134.4	34.2	38.1	33.8	36.3	142.3	150.8	158.4
EBITDA	4.0	3.9	0.0	4.1	11.9	1.8	4.8	3.6	4.0	14.1	18.2	21.2
EBITDA margin (%)	13.0	11.7	-0.1	11.1	8.9	5.2	12.5	10.5	11.0	9.9	12.1	13.4
EBIT	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	1.7	2.4	7.1	11.3	14.3
EBIT margin (%)	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	5.0	6.6	5.0	7.5	9.0
Net financial items	0.5	-0.5	0.4	0.0	0.4	0.5	1.9	1.6	-0.2	3.8	-0.8	0.9
Pre-tax profit	2.9	1.9	-1.3	0.7	4.2	0.5	4.9	3.3	2.2	10.9	10.5	15.1
Tax	-0.9	-0.5	-0.9	-0.2	-2.5	-0.5	-1.0	-1.2	-0.5	-3.2	-3.0	-4.4
Tax rate (%)	30.8	25.4	-68.9	31.2	60.2	104.4	20.0	35.6	21.0	29.0	29.0	29.0
Net profit	2.0	1.4	-2.2	0.5	1.7	0.0	3.9	2.1	1.7	7.8	7.5	10.7
EPS	0.17	0.12	-0.19	0.04	0.14	0.00	0.33	0.18	0.15	0.65	0.63	0.90
EPS adjusted (diluted no. of shares)	0.17	0.12	-0.19	0.04	0.14	0.00	0.33	0.18	0.15	0.65	0.63	0.90
Dividend per share	0.00	0.00	0.00	0.00	0.20	0.00	0.00	0.00	0.00	0.25	0.30	0.32
SALES, EURm												
Exel Composites	31.0	33.5	33.4	36.5	134.4	34.2	38.1	33.8	36.3	142.3	150.8	158.4
Total	31.0	33.5	33.4	36.5	134.4	34.2	38.1	33.8	36.3	142.3	150.8	158.4
SALES GROWTH, Y/Y %												
Exel Composites	11.3	23.3	28.0	32.6	23.7	10.3	13.5	1.2	-0.5	5.9	6.0	5.0
Total	11.3	23.3	28.0	32.6	23.7	10.3	13.5	1.2	-0.5	5.9	6.0	5.0
EBIT, EURm												
Exel Composites	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	1.7	2.4	7.1	11.3	14.3
Total	2.4	2.4	-1.7	0.6	3.7	0.0	3.0	1.7	2.4	7.1	11.3	14.3
EBIT margin, %										*	•	
Exel Composites	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	5.0	6.6	5.0	7.5	9.0
Total	7.8	7.0	-5.1	1.8	2.8	0.1	7.9	5.0	6.6	5.0	7.5	9.0

Chemicals/Finland, November 4, 2022 Company update

Sales	86.3							2024E
	86.3	96.6	103.8	108.6	134.4	142.3	150.8	158.4
Sales growth (%)	18.1	11.9	7.5	4.6	23.7	5.9	6.0	5.0
EBITDA	9.3	7.7	10.7	15.3	11.9	14.1	18.2	21.2
EBITDA margin (%)	10.8	8.0	10.3	14.1	8.9	9.9	12.1	13.4
Depreciation	-3.2	-5.5	-5.6	-5.8	-8.2	-7.0	-6.9	-7.0
EBITA	6.1	2.2	5.1	9.4	3.7	7.1	11.3	14.3
Goodwill amortization / writedown	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	6.1	2.2	5.1	9.4	3.7	7.1	11.3	14.3
EBIT margin (%)	7.1	2.3	4.9	8.7	2.8	5.0	7.5	9.0
Reported EBIT	6.1	2.2	5.1	9.4	3.7	7.1	11.3	14.3
EBIT margin (reported) (%)	7.1	2.3	4.9	8.7	2.8	5.0	7.5	9.0
Net financials	-0.7	-0.5	-1.2	-2.3	0.4	3.8	-0.8	0.9
Pre-tax profit	5.4	1.7	3.9	7.1	4.2	10.9	10.5	15.1
Taxes	-1.2	-1.3	-1.5	-1.7	-2.5	-3.2	-3.0	-4.4
Minority shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net profit	4.2	0.4	2.4	5.4	1.7	7.8	7.5	10.7
Cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-cash NRIs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET, EURm								
Assets								
Fixed assets	16	21	23	30	34	34	34	35
Goodwill	13	13	13	13	13	13	13	13
Right of use assets	0	5	5	3	3	3	4	4
Inventory	12	15	17	16	24	25	27	28
Receivables	15	20	20	21	26	28	30	31
Liquid funds	8	5	7	12	16	17	18	18
Total assets	64	79	85	97	118	122	126	131
Liabilities								
Shareholder's equity	29	26	26	29	31	37	41	48
Minority interest	0	0	0	0	0	0	0	0
Convertibles	0	0	0	0	0	0	0	0
Lease liabilities	0	3	4	2	2	3	4	4
Deferred taxes	0	0	0	0	0	0	0	0
Interest bearing debt	16	30	32	40	50	45	43	38
Non-interest bearing current liabilities	18	18	21	24	32	34	36	38
Other interest-free debt	0	2	2	2	3	3	3	3
Total liabilities	64	79	85	97	118	122	126	131
CASH FLOW, EURm								
+ EBITDA	9	8	11	15	12	14	18	21
- Net financial items	-1	0	-1	-2	0	4	-1	1
- Taxes	-1	-2	-2	-2	-3	-3	-3	-4
- Increase in Net Working Capital	-3	-4	1	3	-5	-1	-1	-1
+/- Other	1	0	0	0	0	0	0	0
= Cash flow from operations	5	1	8	13	5	14	13	17
- Capex	-3	-10	-8	-13	-11	-7	-7	-7
- Acquisitions	0	0	0	0	0	0	0	0
+ Divestments	0	0	0	0	0	0	0	0
= Free cash flow	1	-9	1	0	-6	6	6	9
+/- New issues/buybacks	-1	0	0	-1	3	0	0	0
- Paid dividend	-1	-4	-2	-2	-2	-2	-3	-4
	1	9	3	7	9	-3	-2	-5
+/- Other	1	9						

Chemicals/Finland, November 4, 2022 Company update

KEY FIGURES	2018	2019	2020	2021	2022E	2023E	2024E
M-cap	48	78	88	94	62	62	62
Net debt (excl. convertibles)	28	29	30	36	32	29	24
Enterprise value	76	107	118	131	94	91	85
Sales	97	104	109	134	142	151	158
EBITDA	8	11	15	12	14	18	21
EBIT	2	5	9	4	7	11	14
Pre-tax	2	4	7	4	11	11	15
Earnings	0	2	5	2	8	7	11
Equity book value (excl. minorities)	26	26	29	31	37	41	48
Valuation multiples							
EV/sales	0.8	1.0	1.1	1.0	0.7	0.6	0.5
EV/EBITDA	9.9	10.0	7.7	10.9	6.7	5.0	4.0
EV/EBITA	34.5	21.0	12.5	34.9	13.2	8.1	6.0
EV/EBIT	34.5	21.0	12.5	34.9	13.2	8.1	6.0
EV/OCF	84.3	12.9	8.8	27.2	6.9	6.9	5.1
EV/FCFF	-6.6	32.5	52.9	-26.0	19.6	12.2	8.8
P/FCFE	-5.5	110.9	179.1	-15.3	9.6	10.5	6.7
P/E	119.0	32.5				8.3	5.8
P/B		32.5	16.4	57.0	8.0		
·	1.8		3.1	3.0	1.7	1.5	1.3
Target EV/EBITDA	0.0	0.0	0.0	0.0	7.8	5.8	4.8
Target EV/EBIT	0.0	0.0	0.0	0.0	15.4	9.4	7.1
Target EV/FCF	0.0	0.0	0.0	0.0	17.1	18.1	10.9
Target P/B	0.0	0.0	0.0	0.0	2.1	1.9	1.6
Target P/E	0.0	0.0	0.0	0.0	10.0	10.4	7.2
Per share measures							
Number of shares	11,897	11,897	11,897	11,897	11,897	11,897	11,897
Number of shares (diluted)	11,897	11,897	11,897	11,897	11,897	11,897	11,897
EPS	0.03	0.20	0.45	0.14	0.65	0.63	0.90
Operating cash flow per share	0.08	0.70	1.12	0.40	1.15	1.11	1.40
Free cash flow per share	-0.73	0.06	0.04	-0.52	0.54	0.49	0.78
Book value per share	2.16	2.21	2.41	2.62	3.08	3.45	4.06
Dividend per share	0.18	0.18	0.20	0.20	0.25	0.30	0.32
Dividend payout ratio, %	535.4	89.2	44.3	143.7	38.4	47.8	35.4
Dividend yield, %	4.5	2.7	2.7	2.5	4.8	5.8	6.2
FCF yield, %	-18.3	0.9	0.6	-6.5	10.4	9.5	14.9
Efficiency measures							
ROE							
	1.5	9.2	19.5	5.5	22.9	19.2	24.0
ROCE	1.5 4.5	9.2 8.6	19.5 14.4	5.5 5.1	22.9 8.7	19.2 11.7	24.0 13.4
ROCE Financial ratios							
Financial ratios	4.5	8.6	14.4	5.1	8.7	11.7	13.4
Financial ratios Inventories as % of sales Receivables as % of sales	4.5 15.7	8.6	14.4	5.1 17.8	17.8	11.7	13.4
Financial ratios Inventories as % of sales	4.5 15.7 20.8	16.3 19.2	14.4 14.9 19.2	5.1 17.8 19.6	17.8 19.6	11.7 17.8 19.6	13.4 17.8 19.6
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales	4.5 15.7 20.8 19.2	16.3 19.2 20.2	14.4 14.9 19.2 22.0	5.1 17.8 19.6 23.8	17.8 19.6 23.8	11.7 17.8 19.6 23.8	13.4 17.8 19.6 23.8
Financial ratios Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, %	4.5 15.7 20.8 19.2 16.1	16.3 19.2 20.2 14.1 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7	17.8 19.6 23.8 12.7 5.1	11.7 17.8 19.6 23.8 12.8 4.9	13.4 17.8 19.6 23.8 12.8
Financial ratios  Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), %	4.5 15.7 20.8 19.2 16.1 9.9 9.9	16.3 19.2 20.2 14.1 7.3 7.3	14.4 14.9 19.2 22.0 11.2 11.9	5.1 17.8 19.6 23.8 12.7 8.2 8.2	17.8 19.6 23.8 12.7 5.1	11.7 17.8 19.6 23.8 12.8 4.9	13.4 17.8 19.6 23.8 12.8 4.7 4.7
Financial ratios  Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	8.7 17.8 19.6 23.8 12.7 5.1 5.1	11.7 17.8 19.6 23.8 12.8 4.9 4.9	13.4 17.8 19.6 23.8 12.8 4.7 4.7 0.5
Financial ratios  Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA Net debt/EBITDA, book-weighted	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5 3.7	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3 2.7	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1 2.0	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4 3.0	8.7 17.8 19.6 23.8 12.7 5.1 0.3 2.3	11.7 17.8 19.6 23.8 12.8 4.9 4.9 0.4 1.6	13.4 17.8 19.6 23.8 12.8 4.7 4.7 0.5 1.1
Financial ratios  Inventories as % of sales Receivables as % of sales Non-interest bearing liabilities as % of sales NWC/sales, % Operative CAPEX/sales, % CAPEX/sales (incl. acquisitions), % FCFF/EBITDA	4.5 15.7 20.8 19.2 16.1 9.9 9.9 -1.5	8.6 16.3 19.2 20.2 14.1 7.3 7.3 0.3	14.4 14.9 19.2 22.0 11.2 11.9 11.9 0.1	5.1 17.8 19.6 23.8 12.7 8.2 8.2 -0.4	8.7 17.8 19.6 23.8 12.7 5.1 5.1	11.7 17.8 19.6 23.8 12.8 4.9 4.9	17.8 19.6 23.8 12.8 4.7 4.7 0.5

Chemicals/Finland, November 4, 2022 Company update

COMPANY DESCRIPTION: Exel Composites manufactures composites profiles for various demanding, mainly industrial end-use, applications. Exel's customer base includes companies operating in industries such as wind energy, transportation and telecommunications. Exel Composites is one of the largest manufacturers of pultruded composites profiles globally and currently operates eight manufacturing plants on three continents.

INVESTMENT CASE: Our positive view is based on good long-term composites demand outlook, coupled with the fact that Exel Composites' current manufacturing footprint could support annual revenue in the EUR 150m ballpark i.e. there's still plenty of room to improve delivery volumes. Exel's rather high fixed cost base translates to meaningful operating leverage, and thus higher revenues should lead to improving operating margins. The company is also progressing well with its cost savings program. Operating profit could further significantly improve if good execution continues. Recently the wind energy sector has provided great lift for volumes; other attractive applications include e.g. transportation industry profiles.

OWNERSHIP STRUCTURE	SHARES	EURm	%
Sijoitusrahasto Taaleritehdas Mikro Markka	800,000	4.160	6.7%
OP-Finland Small Firms Fund	590,119	3.069	5.0%
Ilmarinen Mutual Pension Insurance	496,547	2.582	4.2%
Op-Suomi Mikroyhtiöt -Erikoissijoitusrahasto	420,000	2.184	3.5%
Phoebus Fund	370,000	1.924	3.1%
Säästöpankki Pienyhtiöt	288,710	1.501	2.4%
Nelimarkka Heikki Antero	213,545	1.110	1.8%
Veritas Pension Insurance Company Ltd.	207,479	1.079	1.7%
Säästöpankki Kotimaa	132,680	0.690	1.1%
Sumato Oy	131,821	0.685	1.1%
Ten largest	3,650,901	18.985	31%
Residual	8,245,942	42.879	69%
Total	11,896,843	61.864	100%

EARNINGS CALENDAR		
February 17, 2023	FY 2022 Results	
May 02, 2023	Q1 report	
August 18, 2023	Q2 report	
November 03, 2023	Q3 report	
OTHER EVENTS		

COMPANY MISCELLANEOUS

CEO: Jouni Heinonen Mäkituvantie 5 01510 Vantaa
CFO: Mikko Rummukainen Tel: +358 20 7541 200

IR:

Chemicals/Finland, November 4, 2022 Company update

### **DEFINITIONS**

P/BV Price per share Shareholders' equity + taxed provisions per share  Market cap OCF (C Price per share * Number of shares  EV (Enterprise value) Market cap + net debt + minority interest at market value - share of associated companies at market value  EV/Sales EV/Sales Enterprise value Sales  EV/EBITDA Enterprise value Earnings before interest, tax, depreciation and amortization  EV/EBIT Net we Operating profit  Net debt Interest bearing debt - financial assets  Gearin Balance sheet total	Dividend for the financial period per share  Dividend for the financial period per share  Dividend for the financial period per share  Perating cash flow)  EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments  ee cash flow)  Perating cash flow – operative CAPEX – acquisitions + divestments  Id, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales  Perking capital
Price per share Shareholders' equity + taxed provisions per share    Description	perating cash flow)  EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments  ee cash flow)  erating cash flow – operative CAPEX – acquisitions + divestments  Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
Shareholders' equity + taxed provisions per share  Market cap  Price per share * Number of shares  EV (Enterprise value)  Market cap + net debt + minority interest at market value - share of associated companies at market value  EV/Sales  Enterprise value Sales  EV/EBITDA  Enterprise value Earnings before interest, tax, depreciation and amortization  EV/EBIT  Net wo  Interest bearing debt - financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	perating cash flow)  EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments  ee cash flow)  erating cash flow – operative CAPEX – acquisitions + divestments  Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
EV (Enterprise value)  Market cap + net debt + minority interest at market value - share of associated companies at market value  EV/Sales  Enterprise value Sales  EV/EBITDA  Enterprise value Earnings before interest, tax, depreciation and amortization  EV/EBIT  Net we salue Operating profit  Net debt  Interest bearing debt - financial assets  Balance sheet total  Div yield, %  PCF (Friends)  FCF (Friends)  Operating - share value -	EBITDA – Net financial items – Taxes – Increase in working capital – Cash NRIs ± Other adjustments  ee cash flow)  erating cash flow – operative CAPEX – acquisitions + divestments  Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
EV/EBITDA  Enterprise value  Enterprise value  Enterprise value  Enterprise value  Enterprise value  Earnings before interest, tax, depreciation and amortization  EV/EBIT  Enterprise value  Operation  Enterprise value  Earnings before interest, tax, depreciation and amortization  EV/EBIT  Net work  Operation  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  FCF (Financial asset)  FCF yield  Operation  Oper	capital – Cash NRIs ± Other adjustments  ee cash flow)  trating cash flow – operative CAPEX – acquisitions + divestments  Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions  Sales
Market cap + net debt + minority interest at market value - share of associated companies at market value  EV/Sales  Enterprise value Sales  EV/EBITDA  Enterprise value Earnings before interest, tax, depreciation and amortization  EV/EBIT  Enterprise value Operating profit  Net work  Interest bearing debt - financial assets  Gearin  Balance sheet total  Div yield, %  Debt/E	erating cash flow – operative CAPEX – acquisitions + divestments  Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
Share of associated companies at market value  EV/Sales  Enterprise value Sales  Enterprise value Earnings before interest, tax, depreciation and amortization  EV/EBIT  Enterprise value Operating profit  Net wo  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	Ild, %  Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
Enterprise value  Enterprise value  Enterprise value  Earnings before interest, tax, depreciation and amortization  EV/EBIT  Net wo  Enterprise value Operating profit  Net debt  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	Free cash flow Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
Enterprise value   Enterprise value   Earnings before interest, tax, depreciation and amortization	Market cap  ive CAPEX/sales  Capital expenditure – divestments – acquisitions Sales
Enterprise value  Earnings before interest, tax, depreciation and amortization  EV/EBIT  Enterprise value Operating profit  Net debt  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	Capital expenditure – divestments – acquisitions Sales
Earnings before interest, tax, depreciation and amortization  EV/EBIT  Enterprise value Operating profit  Net debt  Capita  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	Sales
Enterprise value Operating profit  Net debt Capita Interest bearing debt – financial assets  Total assets Balance sheet total  Div yield, %  Debt/E	orking capital
Operating profit  Net debt  Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	5 - 1 -
Interest bearing debt – financial assets  Total assets  Balance sheet total  Div yield, %  Debt/E	Current assets – current liabilities
Total assets  Balance sheet total  Div yield, %  Debt/E	employed/Share
Balance sheet total  Div yield, %  Debt/E	Total assets – non-interest bearing debt  Number of shares
Div yield, % Debt/E	9
	Net debt Equity
Dividend per share	quity, %
Price per share	Interest bearing debt Shareholders' equity + minority interest + taxed provisions
Payout ratio, % Equity	ratio, %
Total dividends  Earnings before extraordinary items and taxes – income taxes + minority interest	Shareholders' equity + minority interest + taxed provisions Total assets – interest-free loans
ROCE, % CAGR,	%
Profit before extraordinary items + interest expenses+ other financial costs  Balance sheet total – non-interest bearing debt (average)	Cumulative annual growth rate = Average growth per year
ROE, %	
Profit before extraordinary items and taxes – income taxes  Shareholder's equity + minority interest + taxed provisions (average)	

Chemicals/Finland, November 4, 2022 Company update

#### Important Disclosures


Evli Research Partners Plc ("ERP") uses 12-month target prices. Target prices are defined by utilizing analytical techniques based on financial theory including (but not limited to) discounted cash flow analysis and comparative valuation. The selection of valuation methods depends on different circumstances. Target prices may be altered on the basis of new information coming to light in the underlying company or changes in interest rates, changes in foreign exchange rates, other securities prices or market indices or outlook for the aforementioned factors or other factors that may change the conditions of financial markets. Recommendations and changes by analysts are available at <u>Analysts' recommendations and ratings revisions</u>.

Investment recommendations are defined as follows:

Target price compared to share price Recommendation

< -10 % SELL -10 - (+10) % HOLD > 10 % BUY

ERP's investment recommendation of the analyzed company is updated at least 2 times per year.



The graph above shows the distribution of ERP's recommendations of companies under coverage in 11th of May 2020. If recommendation is not given, it is not mentioned here.

### Name(s) of the analyst(s): Ilvonen

This research report has been prepared by Evli Research Partners Plc ("ERP" or "Evli Research"). ERP is a subsidiary of Evli Plc. Production of the investment recommendation has been concluded on [4.11.2022, 8:45]. This report has been published on [4.11.2022, 9:05].

None of the analysts contributing to this report, persons under their guardianship or corporations under their control have a position in the shares of the company or related securities.

The date and time for any price of financial instruments mentioned in the recommendation refer to the previous trading day's closing price(s) unless otherwise stated in the report.

Each analyst responsible for the content of this report assures that the expressed views accurately reflect the personal views of each analyst on the covered companies and securities. Each analyst assures that (s)he has not been, nor are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

Companies in the Evli Group, affiliates or staff of companies in the Evli Group, may perform services for, solicit business from, hold long or short positions in, or otherwise be interested in the investments (including derivatives) of any company mentioned in the publication or report.

Neither ERP nor any company within the Evli Group have managed or co-managed a public offering of the company's securities during the last 12 months prior to, received compensation for investment banking services from the company during the last 12 months prior to the publication of the research report.

ERP has signed an agreement with the issuer of the financial instruments mentioned in the recommendation, which includes production of research reports. This assignment has a limited economic and financial impact on ERP and/or EVIi. Under the assignment ERP performs services including, but not limited to, arranging investor meetings or –events, investor relations communication advisory and production of research material.

ERP or another company within the Evli Group does not have an agreement with the company to perform market making or liquidity providing services.

For the prevention and avoidance of conflicts of interests with respect to this report, there is an information barrier (Chinese wall) between Investment

### **EVLI EQUITY RESEARCH**

## **EXEL COMPOSITES**

Chemicals/Finland, November 4, 2022 Company update

Research and Corporate Finance units concerning unpublished investment banking services to the company. The remuneration of the analyst(s) is not tied directly or indirectly to investment banking transactions or other services performed by Evli Plc or any company within Evli Group.

This report has not been disclosed to the company prior to its dissemination.

This report is provided and intended for informational purposes only and may not be used or considered under any circumstances as an offer to sell or buy any securities or as advice to trade any securities.

This report is based on sources ERP considers to be correct and reliable. The sources include information providers Reuters and Bloomberg, stock-exchange releases from the companies and other company news, Statistics Finland and articles in newspapers and magazines. However, ERP does not guarantee the materialization, correctness, accuracy or completeness of the information, opinions, estimates or forecasts expressed or implied in the report. In addition, circumstantial changes may have an influence on opinions and estimates presented in this report. The opinions and estimates presented are valid at the moment of their publication and they can be changed without a separate announcement. Neither ERP nor any company within the Evli Group are responsible for amending, correcting or updating any information, opinions or estimates contained in this report. Neither ERP nor any company within the Evli Group will compensate any direct or consequential loss caused by or derived from the use of the information represented in this publication.

All information published in this report is for the original recipient's private and internal use only. ERP reserves all rights to the report. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in any retrieval system of any nature, without the written permission of ERP.

This report or its copy may not be published or distributed in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore or South Africa. The publication or distribution of this report in certain other jurisdictions may also be restricted by law. Persons into whose possession this report comes are required to inform themselves about and to observe any such restrictions.

Evli Plc is not registered as a broker-dealer with the U. S. Securities and Exchange Commission ("SEC"), and it and its analysts are not subject to SEC rules on securities analysts' certification as to the currency of their views reflected in the research report. Evli is not a member of the Financial Industry Regulatory Authority ("FINRA"). It and its securities analysts are not subject to FINRA's rules on Communications with the Public and Research Analysts and Research Reports and the attendant requirements for fairness, balance and disclosure of potential conflicts of interest. This research report is only being offered in U.S. by Auerbach Grayson & Company, LLC (Auerbach Grayson) to Major U.S. Institutional Investors and is not available to, and should not be used by, any U.S. person or entity that is not a Major U.S. Institutional Investor. Auerbach Grayson is a broker-dealer registered with the U.S. Securities and Exchange Commission and is a member of the FINRA. U.S. entities seeking more information about any of the issuers or securities discussed in this report should contact Auerbach Grayson. The securities of non-U.S. issuers may not be registered with or subject to SEC reporting and other requirements.

ERP is not a supervised entity but its parent company Evli Plc is supervised by the Finnish Financial Supervision Authority.

Chemicals/Finland, November 4, 2022 Company update

## Contact information SALES, TRADING AND RESEARCH

Equity, ETF and Derivatives Sales		Trading	
Joachim Dannberg Ari Laine Kimmo Lilja	+358 9 4766 9123 +358 9 4766 9115 +358 9 4766 9130	Lauri Vehkaluoto (Head) Pasi Väisänen Antti Kässi Miika Ronkanen	+358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120 +358 9 4766 9120
Structured Investments		Equity Research	
Heikki Savijoki Aki Lakkisto	+358 9 4766 9726 +358 9 4766 9123	Jonas Forslund Joonas Ilvonen Jerker Salokivi Teemu Reiman	+358 9 4766 9314 +358 44 430 9071 +358 9 4766 9149 +358 40 352 6175
Evli Investment Solutions			
Johannes Asuja	+358 9 4766 9205		



EVLI BANK PLC
Aleksanterinkatu 19 A
P.O. Box 1081
FIN-00101 Helsinki, FINLAND
Phone +358 9 476 690
Fax +358 9 634 382
Internet www.evli.com
E-mail firstname.lastname@evli.com

EVLI BANK PLC, STOCKHOLMSFILIAL Regeringsgatan 67 P.O. Box 16354 SE-103 26 Stockholm Sverige stockholm@evli.com Tel +46 (0)8 407 8000 Fax +46 (0)8 407 8001